Matthew Henn (Seres Therapeutics): ‘Microbiome research will have a large impact on human health’

Staff editor

06.05.2021

Watch our interview with Matthew Henn, Executive Vice President and Chief Scientific Officer of Seres Therapeutics.

Watch our interview with Matthew Henn, Executive Vice President and Chief Scientific Officer of Seres Therapeutics.

Subscribe to MicrobiomePost newsletter

Take full advantage of MicrobiomePost‘s features.

Via Podgora 12/A, 20122, Milan, Italy – VAT: IT05299040963

This communication is only intended for business-to-business and health care professionals.
This communication is not intended for consumers of final consumer goods.
Nothing on this page is meant to be perceived as an approved claim.

Matthew Henn (Seres Therapeutics): ‘Microbiome research will have a large impact on human health’

Latest related content

Antibiotics can weaken vaccine response by disrupting gut bacteria

Riboflavin: the vitamin that helps good bacteria work better

Microbiota-derived bile acids may boost immune cells to fight cancer

Diet shapes gut microbiota to protect mice against C. difficile

Microbe-doping: could tuning the gut count as cheating?

Clinically tested probiotics for common colds management designed by SynBalance

Latest News